Works matching AU Xu, Minhui


Results: 95
    1
    2
    3

    Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer.

    Published in:
    Journal of Clinical Medicine, 2019, v. 8, n. 4, p. 489, doi. 10.3390/jcm8040489
    By:
    • Sakamoto, Shinichi;
    • Maimaiti, Maihulan;
    • Xu, Minhui;
    • Kamada, Shuhei;
    • Yamada, Yasutaka;
    • Kitoh, Hiroki;
    • Matsumoto, Hiroaki;
    • Takeuchi, Nobuyoshi;
    • Higuchi, Kosuke;
    • Uchida, Haruhito A.;
    • Komiya, Akira;
    • Nagata, Maki;
    • Nakatsu, Hiroomi;
    • Matsuyama, Hideyasu;
    • Akakura, Koichiro;
    • Ichikawa, Tomohiko
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33

    MicroRNAs and cell cycle of malignant glioma.

    Published in:
    International Journal of Neuroscience, 2016, v. 126, n. 1, p. 1, doi. 10.3109/00207454.2015.1017881
    By:
    • Ouyang, Qing;
    • Xu, Lunshan;
    • Cui, Hongjuan;
    • Xu, Minhui;
    • Yi, Liang
    Publication type:
    Article
    34
    35
    36
    37

    The LAT1 inhibitor JPH203 suppresses the growth of castration‐resistant prostate cancer through a CD24‐mediated mechanism.

    Published in:
    Cancer Science, 2024, v. 115, n. 7, p. 2461, doi. 10.1111/cas.16191
    By:
    • Saito, Shinpei;
    • Ando, Keisuke;
    • Sakamoto, Shinichi;
    • Xu, Minhui;
    • Yamada, Yasutaka;
    • Rii, Junryo;
    • Kanaoka, Sanji;
    • Wei, Jiaxing;
    • Zhao, Xue;
    • Pae, Sangjon;
    • Kanesaka, Manato;
    • Goto, Yusuke;
    • Sazuka, Tomokazu;
    • Imamura, Yusuke;
    • Reien, Yoshie;
    • Hamaguchi‐Suzuki, Norie;
    • Saito, Shota;
    • Hirayama, Yuri;
    • Hashimoto, Hirofumi;
    • Kanai, Yoshikatsu
    Publication type:
    Article
    38

    L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity.

    Published in:
    Cancer Science, 2024, v. 115, n. 3, p. 937, doi. 10.1111/cas.16062
    By:
    • Rii, Junryo;
    • Sakamoto, Shinichi;
    • Mizokami, Atsushi;
    • Xu, Minhui;
    • Fujimoto, Ayumi;
    • Saito, Shinpei;
    • Koike, Hidekazu;
    • Tamura, Takaaki;
    • Arai, Takayuki;
    • Yamada, Yasutaka;
    • Goto, Yusuke;
    • Sazuka, Tomokazu;
    • Imamura, Yusuke;
    • Suzuki, Kazuhiro;
    • Kanai, Yoshikatsu;
    • Anzai, Naohiko;
    • Ichikawa, Tomohiko
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46

    The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2.

    Published in:
    Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-90748-9
    By:
    • Maimaiti, Maihulan;
    • Sakamoto, Shinichi;
    • Sugiura, Masahiro;
    • Kanesaka, Manato;
    • Fujimoto, Ayumi;
    • Matsusaka, Keisuke;
    • Xu, Minhui;
    • Ando, Keisuke;
    • Saito, Shinpei;
    • Wakai, Ken;
    • Imamura, Yusuke;
    • Nakayama, Keiichi;
    • Kanai, Yoshikatsu;
    • Kaneda, Atsushi;
    • Ikehara, Yuzuru;
    • Ikeda, Jun-Ichiro;
    • Anzai, Naohiko;
    • Ichikawa, Tomohiko
    Publication type:
    Article
    47
    48
    49
    50